iData Insights

Kite Pharma, Inc. - Product Pipeline Review – 2015 Is Released

Press Release   •   Feb 09, 2016 16:28 IST

This report provides comprehensive information on the current therapeutic developmental pipeline of Kite Pharma, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Kite Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Kite Pharma, Inc.s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Kite Pharma, Inc.s pipeline products Reasons to buy - Evaluate Kite Pharma, Inc.s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Kite Pharma, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Kite Pharma, Inc. s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Kite Pharma, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kite Pharma, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Kite Pharma, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179155/kite-pharma-inc-product-pipeline-review-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179155/kite-pharma-inc-product-pipeline-review-2015

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Kite Pharma, Inc. Snapshot 5

Kite Pharma, Inc. Overview 5

Key Information 5

Key Facts 5

Kite Pharma, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Kite Pharma, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Kite Pharma, Inc. - Pipeline Products Glance 11

Kite Pharma, Inc. - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Kite Pharma, Inc. - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Kite Pharma, Inc. - Unknown Stage Pipeline Products 14

Unknown Products/Combination Treatment Modalities 14

Kite Pharma, Inc. - Drug Profiles 15

Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

KTEC-19 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Cellular Immunotherapy to Target EGFR vIII for Glioblastoma, Brain Cancer, Head and neck cancer 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Cellular Immunotherapy to Target MAGE A3 for Oncology 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Cellular Immunotherapy to Target MAGE A3 and A6 for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Cellular Immunotherapy for Hematological Malignancies and Solid Tumors 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Cellular Immunotherapy to Target SSX2 for Solid Tumor 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Kite Pharma, Inc. - Pipeline Analysis 31

Kite Pharma, Inc. - Pipeline Products by Target 31

Kite Pharma, Inc. - Pipeline Products by Route of Administration 32

Kite Pharma, Inc. - Pipeline Products by Molecule Type 33

Kite Pharma, Inc. - Pipeline Products by Mechanism of Action 34

Kite Pharma, Inc. - Recent Pipeline Updates 35

Kite Pharma, Inc. - Dormant Projects 41

Kite Pharma, Inc. - Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Kite Pharma, Inc. Snapshot 5

Kite Pharma, Inc. Overview 5

Key Information 5

Key Facts 5

Kite Pharma, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Kite Pharma, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Kite Pharma, Inc. - Pipeline Products Glance 11

Kite Pharma, Inc. - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Kite Pharma, Inc. - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Kite Pharma, Inc. - Unknown Stage Pipeline Products 14

Unknown Products/Combination Treatment Modalities 14

Kite Pharma, Inc. - Drug Profiles 15

Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

KTEC-19 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Cellular Immunotherapy to Target EGFR vIII for Glioblastoma, Brain Cancer, Head and neck cancer 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Cellular Immunotherapy to Target MAGE A3 for Oncology 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Cellular Immunotherapy to Target MAGE A3 and A6 for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Cellular Immunotherapy for Hematological Malignancies and Solid Tumors 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Cellular Immunotherapy to Target SSX2 for Solid Tumor 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Kite Pharma, Inc. - Pipeline Analysis 31

Kite Pharma, Inc. - Pipeline Products by Target 31

Kite Pharma, Inc. - Pipeline Products by Route of Administration 32

Kite Pharma, Inc. - Pipeline Products by Molecule Type 33

Kite Pharma, Inc. - Pipeline Products by Mechanism of Action 34

Kite Pharma, Inc. - Recent Pipeline Updates 35

Kite Pharma, Inc. - Dormant Projects 41

Kite Pharma, Inc. - Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

Read More http://www.idatainsights.com/reports-landing-page.php?id=179155/kite-pharma-inc-product-pipeline-review-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.